rising pharma holding, inc.
7 recalls on record
R
Rising Pharma Holding, Inc. — Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC 57237-018-99
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.
FDAHealth
R
Rising Pharma Holding, Inc. — Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
FDAHealth
R
Rising Pharma Holding, Inc. — Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswic
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
FDAHealth
R
Rising Pharma Holding, Inc. — Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ NDC 57237-017-60
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
FDAHealth
R
Rising Pharma Holding, Inc. — Duloxetine Delayed-Release Capsules USP, 30 mg, a) 30 count (NDC 57237-018-30), b) 90 count (NDC 57237-018-90) and c) 1000 count (NDC 57237-018-99) bottles, Rx only, Dist
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
FDAHealth
R
Rising Pharma Holding, Inc. — Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
FDAHealth
R
Rising Pharma Holding, Inc. — Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and c) 1000 count (NDC 57237-019-99) bottles, Distributed by: Rising Pharma
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
FDAHealth